Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
Authors
Keywords
-
Journal
ANNALS OF MEDICINE
Volume 54, Issue 1, Pages 2606-2616
Publisher
Informa UK Limited
Online
2022-09-21
DOI
10.1080/07853890.2022.2124449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review
- (2022) Yingbo Huang et al. Translational Lung Cancer Research
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial
- (2021) Corinne Faivre-Finn et al. Journal of Thoracic Oncology
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Females and Males Show Differences in Early-Stage Transcriptomic Biomarkers of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
- (2021) Quewang Liu et al. Diagnostics
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- The impact of sex and gender on immunotherapy outcomes
- (2020) Sabra L. Klein et al. Biology of Sex Differences
- Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1 ‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE ‐042 China Study
- (2020) Yi‐Long Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial
- (2020) Makoto Nishio et al. Journal of Thoracic Oncology
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
- (2019) Christopher J. D. Wallis et al. JAMA Oncology
- Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out
- (2019) C. Proto et al. CANCER TREATMENT REVIEWS
- Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment
- (2019) F Conforti et al. ANNALS OF ONCOLOGY
- Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis
- (2019) Fabio Conforti et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
- (2019) Shixiang Wang et al. MOLECULES
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer and the Immune System: The History and Background of Immunotherapy
- (2019) Maura Abbott et al. Seminars in Oncology Nursing
- Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
- (2019) Long Pan et al. World Journal of Surgical Oncology
- Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
- (2019) Alejandro Ruiz‐Patiño et al. Thoracic Cancer
- Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer
- (2018) L. Fehrenbacher et al. Journal of Thoracic Oncology
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of estrogen in non-small cell lung cancer and its clinical implications
- (2018) Vianey Rodriguez-Lara et al. Journal of Thoracic Disease
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
- (2018) Antonino Grassadonia et al. Journal of Clinical Medicine
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
- (2017) Dearbhaile C. Collins et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer—Differences between adenocarcinoma and squamous cell carcinoma
- (2014) Tatsuro Okamoto et al. LUNG CANCER
- Are Women Who Smoke at Higher Risk for Lung Cancer Than Men Who Smoke?
- (2013) Sara De Matteis et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sex Disparities in Cancer Mortality and Survival
- (2011) M. B. Cook et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung
- (2010) Ping Yuan et al. PLoS One
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now